Literature DB >> 27956320

Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.

D Citterio1, S Pusceddu1, A Facciorusso1, J Coppa1, M Milione1, R Buzzoni1, M Bongini1, F deBraud2, V Mazzaferro3.   

Abstract

BACKGROUND: Functional well-differentiated neuroendocrine tumours (NET) with liver metastases represent a therapeutic challenge with few alternative options in guidelines. In these patients, the role of surgical resection of the primary tumour is controversial. PATIENTS AND METHODS: From a regional registry collecting somatostatin analogue (SSA)-treated tumours from 1979 to 2005, a series of 139 patients presenting with symptomatic, liver-metastatic, well-differentiated NET (G1-G2, mitoses: ≤20, Ki-67: ≤20%) was prospectively collected and retrospectively analysed. Surgery on either the primary tumour or liver metastases was chosen: 1) when low perioperative risk was predictable; 2) in presence of an impending risk of obstruction, bleeding, or perforation; or 3) if liver metastases were suitable of curative or subtotal (>90%) tumour removal. Impact of the most relevant clinico-pathological parameters on survival was studied.
RESULTS: Median follow-up was 127 months and median survival was 94 months, with 138 vs. 37 months in resected vs. non-resected primary NET (p < 0.001), respectively. In the univariate analysis, prolonged survival was significantly associated with primary tumour resection (p < 0.001), resection of liver metastases (p = 0.002), site of primary (carcinoid vs. pancreatic, p = 0.018), basal chromogranin-A (CgA) <200 ng/mL (p = 0.001), and absence of diarrhea (p = 0.012). Multivariate analysis showed that primary tumour resection was an independent positive prognostic factor (HR = 3.17; 95% CI: 1.77-5.69, p < 0.001), whereas diarrhea, basal CgA ≥200 ng/mL, and high tumour load were independent negative prognostic factors. Also, in 103 patients with non-resectable liver metastases, primary tumour resection was significantly associated with prolonged survival (median 137 vs. 32 months, p < 0.0001).
CONCLUSIONS: Primary tumour resection may improve survival in functional well-differentiated NET with liver metastases.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Carcinoid tumour; Liver metastases; Neuroendocrine tumours; Prognosis; Somatostatin analogues; Surgical treatment

Mesh:

Substances:

Year:  2016        PMID: 27956320     DOI: 10.1016/j.ejso.2016.10.031

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  16 in total

Review 1.  Surgical management of neuroendocrine tumor-associated liver metastases: a review.

Authors:  Miu Yee Chan; Ka Wing Ma; Albert Chan
Journal:  Gland Surg       Date:  2018-02

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 3.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

4.  Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise.

Authors:  Mirco Bartolomei; Alfredo Berruti; Massimo Falconi; Nicola Fazio; Diego Ferone; Secondo Lastoria; Giovanni Pappagallo; Ettore Seregni; Annibale Versari
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

5.  Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.

Authors:  Derya Kıvrak Salim; Selami Bayram; İsmail Gömceli; Ayhan Hilmi Çekin; Mustafa Karaca; Murat Koçer; Mustafa Yıldız
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

6.  Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database.

Authors:  Chintan P Shah; Lazarus K Mramba; Rohit Bishnoi; Athira Unnikrishnan; Jennifer M Duff; Sreenivasa R Chandana
Journal:  J Gastrointest Oncol       Date:  2019-10

Review 7.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

8.  Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis.

Authors:  Bo Zhou; Canyang Zhan; Yuan Ding; Sheng Yan; Shusen Zheng
Journal:  Onco Targets Ther       Date:  2018-02-23       Impact factor: 4.147

9.  A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands.

Authors:  C G Genc; H J Klümpen; M G H van Oijen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

10.  Nomograms predict survival outcomes for distant metastatic pancreatic neuroendocrine tumor: A population based STROBE compliant study.

Authors:  Gang Li; Mao-Lin Tian; Yun-Tao Bing; Hang-Yan Wang; Chun-Hui Yuan; Dian-Rong Xiu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.